^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    NRP1 modulator

    Related drugs:
    13d
    Neuropilins in Multiple Sclerosis: Dual Roles of NRP-1 in Neuroinflammation and Neuroprotection. (PubMed, Neuromolecular Med)
    Therapeutic interventions, such as Bu-Shen-Yi-Sui Capsule (BSYSC), FTX-101 (a Sema3A-NRP-1 inhibitor), and tuftsin restore BBB function, reduce inflammation, enhance remyelination, and improve clinical scores. NRP-1 signaling thus exhibits context-dependent dual roles: promoting inflammatory cascades while enabling neuroprotection through regulatory immune networks and oligodendrocyte precursor cell support, highlighting NRP-1 as a therapeutic target in MS.
    Review • Journal
    |
    IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • STAT1 (Signal Transducer And Activator Of Transcription 1) • NRP1 (Neuropilin 1) • SEMA3A (Semaphorin 3A)
    15d
    BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=66, Terminated, Lisata Therapeutics, Inc. | Trial completion date: Mar 2030 --> Apr 2026 | Active, not recruiting --> Terminated; The study was halted prematurely to allow analysis of the results.
    Trial completion date • Trial termination
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • certepetide (LSTA1)
    12ms
    SAD and MAD Study of FTX-101 in Healthy Male Subjects (clinicaltrials.gov)
    P1, N=49, Terminated, Find Therapeutics | N=80 --> 49 | Recruiting --> Terminated; Study's goals have been achieved based on a preliminary analysis of available pharmacokinetic and safety data, which demonstrate that sufficient information has been obtained.
    Enrollment change • Trial termination
    1year
    BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, Lisata Therapeutics, Inc. | Trial completion date: Mar 2026 --> Mar 2030 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • certepetide (LSTA1)
    1year
    FORTIFIDE: Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Lisata Therapeutics, Inc. | Trial completion date: Apr 2025 --> Jan 2040 | Initiation date: Jan 2025 --> Jan 2030 | Trial primary completion date: Apr 2025 --> Jan 2035
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • certepetide (LSTA1)
    1year
    Disruption of Plexin-A1 signaling by FTX-101: mode of action and effect on oligodendrocyte biology. (PubMed, Biomed Pharmacother)
    FTX-101 enhanced the recruitment of oligodendrocytes and promoted myelination, addressing critical medical needs in demyelinating conditions. Specificity, solubility in water, and enduring stability render FTX-101 a highly promising candidate for a first-in-class therapeutic agent.
    Journal
    |
    NRP1 (Neuropilin 1) • PLXNA1 (Plexin A1) • SEMA3A (Semaphorin 3A)
    1year
    FORTIFIDE: Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Lisata Therapeutics, Inc. | N=30 --> 0 | Trial completion date: Sep 2027 --> Apr 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2027 --> Apr 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • certepetide (LSTA1)
    1year
    BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, Lisata Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Apr 2025
    Enrollment closed • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • certepetide (LSTA1)
    over1year
    CENDIFOX: CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, Anup Kasi | Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2023 --> Sep 2025
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)
    over1year
    BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=80, Recruiting, Lisata Therapeutics, Inc. | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • certepetide (LSTA1)
    over1year
    FORTIFIDE: LSTA1 Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Lisata Therapeutics, Inc. | Trial completion date: Jun 2027 --> Sep 2027 | Initiation date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2027 --> Sep 2027
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)
    over1year
    FORTIFIDE: LSTA1 Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Lisata Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)